Research advances in non-cirrhotic intrahepatic presinusoidal portal hypertension

Shuai XIA; Xiaoning WU; Bingqiong WANG; Zhiying HE; Hong YOU

doi:10.3969/j.issn.1001-5256.2022.07.003

Volume 38 Issue 7

Jul. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(7): 1464-1468

PDF( 1852 KB)

Research advances in non-cirrhotic intrahepatic presinusoidal portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.07.003

Shuai XIA^{1, 2},
Xiaoning WU^{1, 2},
Bingqiong WANG^{1, 2},
Zhiying HE^{1, 2},
Hong YOU^{1, 2
,
,
,}

1.
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2.
National Clinical Research Center for Digestive Diseases, Beijing 100050, China

More Information

Corresponding author: YOU Hong, youhongliver@ccmu.edu.cn(ORCID: 0000-0001-9409-1158)
Received Date: 2022-05-04
Accepted Date: 2022-06-05
Published Date: 2022-07-20

Abstract

Abstract

Non-cirrhotic intrahepatic presinusoidal portal hypertension is a subtype of non-cirrhotic portal hypertension, and patients with this disease have the symptoms of portal hypertension and do not have the pathological evidence for liver cirrhosis, with normal or slightly abnormal hepatic venous pressure gradient. This disease is easily missed or misdiagnosed due to its complex etiology; therefore, radiological examination and histological examination should be combined in clinical practice to make a confirmed diagnosis, and related therapies should be initiated at the right time to reduce portal venous pressure. Further studies are needed to verify the efficacy of prophylactic anticoagulant therapy.
- Noncirrhotic Portal Hypertension,
- Hepatic Veno-Occlusive Disease,
- Diagnosis

FullText(HTML)

References(33)

References

[1]	HE FL, MA L, LI YR, et al. Non-cirrhotic portal hypertension: the highlight of its diagnosis[J]. J Prac Hepatol, 2022, 25(1): 1-4. DOI: 10.3969/j.issn.1672-5069.2022.01.001. 何福亮, 马琳, 李悦榕, 等. 非肝硬化门静脉高压的临床诊断[J]. 实用肝脏病杂志, 2022, 25(1): 1-4. DOI: 10.3969/j.issn.1672-5069.2022.01.001.
[2]	KMEID M, LIU X, BALLENTINE S, et al. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: review of current data[J]. Gastroenterology Res, 2021, 14(2): 49-65. DOI: 10.14740/gr1376.
[3]	ZHOU H, FENG XN, REN H, et al. Clinical features and hepatic venous pressure gradientchanges in patients with noncirrhotic portal hypertension[J]. J Prac Hepatol, 2021, 24(3): 415-418. DOI: 10.3969/j.issn.1672-5069.2021.03.028. 周慧, 冯晓宁, 任浩, 等. 非肝硬化门脉高压患者临床特点分析[J]. 实用肝脏病杂志, 2021, 24(3): 415-418. DOI: 10.3969/j.issn.1672-5069.2021.03.028.
[4]	KHANNA R, SARIN SK. Noncirrhotic portal hypertension: current and emerging perspectives[J]. Clin Liver Dis, 2019, 23(4): 781-807. DOI: 10.1016/j.cld.2019.07.006.
[5]	SCHOUTEN JN, VERHEIJ J, SEIJO S. Idiopathic non-cirrhotic portal hypertension: a review[J]. Orphanet J Rare Dis, 2015, 10: 67. DOI: 10.1186/s13023-015-0288-8.
[6]	NORTHUP PG, GARCIA-PAGAN JC, GARCIA-TSAO G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 73(1): 366-413. DOI: 10.1002/hep.31646.
[7]	ISABEL FIEL M, THUNG SN, HYTIROGLOU P, et al. Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis[J]. Am J Surg Pathol, 2007, 31(4): 607-614. DOI: 10.1097/01.pas.0000213425.76621.f1.
[8]	SCHOUTEN JN, NEVENS F, HANSEN B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study[J]. Aliment Pharmacol Ther, 2012, 35(12): 1424-1433. DOI: 10.1111/j.1365-2036.2012.05112.x.
[9]	BISSONNETTE J, RAUTOU PE, VALLA DC. Idiopathic non-cirrhotic portal hypertension: An update[J]. Presse Med, 2015, 44(10): 1009-1015. DOI: 10.1016/j.lpm.2015.06.007.
[10]	de GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0.
[11]	SIRAMOLPIWAT S, SEIJO S, MIQUEL R, et al. Idiopathic portal hypertension: natural history and long-term outcome[J]. Hepatology, 2014, 59(6): 2276-2285. DOI: 10.1002/hep.26904.
[12]	GUIDO M, SARCOGNATO S, SONZOGNI A, et al. Obliterative portal venopathy without portal hypertension: an underestimated condition[J]. Liver Int, 2016, 36(3): 454-460. DOI: 10.1111/liv.12936.
[13]	GUIDO M, SARCOGNATO S, SACCHI D, et al. Pathology of idiopathic non-cirrhotic portal hypertension[J]. Virchows Arch, 2018, 473(1): 23-31. DOI: 10.1007/s00428-018-2355-8.
[14]	RAJESH S, MUKUND A, SUREKA B, et al. Non-cirrhotic portal hypertension: an imaging review[J]. Abdom Radiol (NY), 2018, 43(8): 1991-2010. DOI: 10.1007/s00261-018-1570-8.
[15]	GUERRA MR, NAINI BV, SCAPA JV, et al. Obliterative portal venopathy: A histopathologic finding associated with chronic antibody-mediated rejection in pediatric liver allografts[J]. Pediatr Transplant, 2018, 22(2): 13124. DOI: 10.1111/petr.13124.
[16]	ETZION O, TAKYAR V, NOVACK V, et al. Spleen and liver volumetrics as surrogate markers of hepatic venous pressure gradient in patients with noncirrhotic portal hypertension[J]. Hepatol Commun, 2018, 2(8): 919-928. DOI: 10.1002/hep4.1198.
[17]	LEE H, REHMAN AU, FIEL MI. Idiopathic noncirrhotic portal hypertension: an appraisal[J]. J Pathol Transl Med, 2016, 50(1): 17-25. DOI: 10.4132/jptm.2015.09.23.
[18]	SCHOUTEN JN, NEVENS F, HANSEN B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study[J]. Aliment Pharmacol Ther, 2012, 35(12): 1424-1433. DOI: 10.1111/j.1365-2036.2012.05112.x.
[19]	de FRANCHIS R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[20]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202. DOI: 10.1016/j.jhep.2015.07.040.
[21]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Corrigendum to 'Baveno Ⅶ - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974][J]. J Hepatol, 2022. DOI: 10.1016/j.jhep.2022.03.024. [Online ahead of print]
[22]	WORRAN K, SEMMLER G, JACHS M, et al. Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(2): e251-e266. DOI: 10.1016/j.cgh.2020.11.039.
[23]	O'BRIEN K, FONT-MONTGOMERY E, LUKOSE L, et al. Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease[J]. J Pediatr Gastroenterol Nutr, 2012, 54(1): 83-89. DOI: 10.1097/MPG.0b013e318228330c.
[24]	LASAGNI A, CADAMURO M, MORANA G, et al. Fibrocystic liver disease: novel concepts and translational perspectives[J]. Transl Gastroenterol Hepatol, 2021, 6: 26. DOI: 10.21037/tgh-2020-04.
[25]	SRINATH A, SHNEIDER BL. Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease[J]. J Pediatr Gastroenterol Nutr, 2012, 54(5): 580-587. DOI: 10.1097/MPG.0b013e31824711b7.
[26]	ALSOMALI MI, YEARSLEY MM, LEVIN DM, et al. Diagnosis of congenital hepatic fibrosis in adulthood[J]. Am J Clin Pathol, 2020, 153(1): 119-125. DOI: 10.1093/ajcp/aqz140.
[27]	ZHAO XY, ZHANG X, WANG TL, et al. Clinical and pathological features of patients with congenital hepatic fibrosis[J]. J Clin Hepatol, 2010, 26(2): 191-193. DOI: 10.3969/j.issn.1001-5256.2010.02.025. 赵新颜, 张新, 王泰龄, 等. 先天性肝纤维化14例临床病理特点[J]. 临床肝胆病杂志, 2010, 26(2): 191-193. DOI: 10.3969/j.issn.1001-5256.2010.02.025.
[28]	AKHAN O, KARAOSMANOǦLU AD, ERGEN B. Imaging findings in congenital hepatic fibrosis[J]. Eur J Radiol, 2007, 61(1): 18-24. DOI: 10.1016/j.ejrad.2006.11.007.
[29]	MAMONE G, CAROLLO V, CORTIS K, et al. Magnetic resonance imaging of fibropolycystic liver disease: the spectrum of ductal plate malformations[J]. Abdom Radiol (NY), 2019, 44(6): 2156-2171. DOI: 10.1007/s00261-019-01966-9.
[30]	WEHRMAN A, KRIEGERMEIER A, WEN J. Diagnosis and management of hepatobiliary complications in autosomal recessive polycystic kidney disease[J]. Front Pediatr, 2017, 5: 124. DOI: 10.3389/fped.2017.00124.
[31]	GARCIA-TSAO G. Liver involvement in hereditary hemorrhagic telangiectasia (HHT)[J]. J Hepatol, 2007, 46(3): 499-507. DOI: 10.1016/j.jhep.2006.12.008.
[32]	IYER VN, SABERI B, HEIMBACH JK, et al. Liver transplantation trends and outcomes for hereditary hemorrhagic telangiectasia in the United States[J]. Transplantation, 2019, 103(7): 1418-1424. DOI: 10.1097/TP.0000000000002491.
[33]	DUMORTIER J, DUPUIS-GIROD S, VALETTE PJ, et al. Recurrence of hereditary hemorrhagic telangiectasia after liver transplantation: clinical implications and physiopathological insights[J]. Hepatology, 2019, 69(5): 2232-2240. DOI: 10.1002/hep.30424.

Relative Articles

[1]	Journal of Hepatology｜Sour neuronal signalling attenuates macrophage mediated liver injury[J]. Journal of Clinical Hepatology, 2025, 41(4): 754-754. doi: 10.12449/JCH2504.gwqkjpwzjj3
[2]	Zhiguo LI, Xun MA, Yongan YE, Xianzhao YANG. Regulatory effect of Kangxian Yiai Prescription in a rat model of precancerous lesions of liver cancer： A study based on the mTOR/HIF-1α/VEGF signaling pathway[J]. Journal of Clinical Hepatology, 2024, 40(10): 2049-2054. doi: 10.12449/JCH241019
[3]	Xing YANG, Shudi LI, Jiangkai LIU, Zhen WANG, Suling LI. Current research status of traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma by regulating the JAK/STAT signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(11): 2718-2729. doi: 10.3969/j.issn.1001-5256.2023.11.030
[4]	Rui SONG, Jing LI, Hongju YANG, Minyue LI, Jing YOU. Role of signal transducer and activator of transcription 1 in regulation of Treg/Th17 balance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2627-2631. doi: 10.3969/j.issn.1001-5256.2022.11.038
[5]	Hong XIANG, Fenglin HU, Xufeng TAO, Xin QI, Jinnan ZHANG, Dong SHANG. Artemisia capillaris Thunb. decoction exerts a protective effect on rats with severe acute pancreatitis by regulating the lncRNA PVT1/miRNA-30a-5p signaling pathway[J]. Journal of Clinical Hepatology, 2021, 37(1): 147-152. doi: 10.3969/j.issn.1001-5256.2021.01.029
[6]	Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
[7]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[8]	Zhihua ZUO, Chuyi ZENG, Yao JIANG, Hualin TAO, Yongcan GUO. Regulatory role of long non-coding RNAs in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1704-1707. doi: 10.3969/j.issn.1001-5256.2021.07.048
[9]	LU NenYuan, ZHONG FangFei, DENG QingMei, YANG YanQi, ZHENG Yang, ZHAO TieJian, LIANG TianJian. Regulatory effect of long non-coding RNAs on liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2811-2814. doi: 10.3969/j.issn.1001-5256.2020.12.035
[10]	Wang ZeXin, Guan LiJun, Li JianMing, Wang ZhiChao, Xue MengRuo, Qin XiaoJun. Effect of targeted regulation of the Wnt2 gene by microRNA( microRNA-21) on the proliferation and migration of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 803-807. doi: 10.3969/j.issn.1001-5256.2020.04.019
[11]	HUANG Qing, LI JingTao, LIU YongGang, WEI HaiLiang, YAN ShuGuang, GUO YingJun, CHANG ZhanJie. Regulatory effect of mTOR pathway-mediated autophagy in liver injury[J]. Journal of Clinical Hepatology, 2020, 36(11): 2621-2625. doi: 10.3969/j.issn.1001-5256.2020.11.051
[12]	Huang XiangJun, Zhang WenXing. Expression features and clinical significance of the microRNA-888 gene family in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 119-122. doi: 10.3969/j.issn.1001-5256.2019.01.022
[13]	Zhao Jing, Yang XingWu, Li JingTao, Wang Qi, Wang Liang, Wang GuoTai. Construction and functional enrichment analysis of circRNA-miRNA-mRNA regulatory network for liver cancer based on high-throughput sequencing[J]. Journal of Clinical Hepatology, 2019, 35(8): 1740-1744. doi: 10.3969/j.issn.1001-5256.2019.08.018
[14]	Meng Jian, Du SongTao, Zhang JingGuang. Clinical effect of recombinant adenovirus containing thymidine kinase suicide gene in preventing postoperative recurrence of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(10): 1944-1948. doi: 10.3969/j.issn.1001-5256.2017.10.019
[15]	Zhang ChuanTao, Gu HaiYing, Huang Qun, Liu YeFang, Wang DeLi, Zheng ZhengLong, Hu Rong, Qiao WeiJuan. Molecular mechanism in the pathogenesis of mild chronic hepatitis B based on microRNA regulation[J]. Journal of Clinical Hepatology, 2016, 32(6): 1130-1134. doi: 10.3969/j.issn.1001-5256.2016.06.022
[16]	Cui XiangHua, Jia JiDong. Research advances in micro RNAs in regulating hepatitis C virus replication and antiviral therapy[J]. Journal of Clinical Hepatology, 2015, 31(5): 800-802. doi: 10.3969/j.issn.1001-5256.2015.05.042
[17]	Gou ZePeng, Wang DeSheng, Zhou Liang, Zhu PuLi, Zhang Yong, Sun Wei. The research progress of STAT3 on the regulation of hepatocellular carcinoma invasion and metastasis[J]. Journal of Clinical Hepatology, 2012, 28(4): 308-311.
[18]	Chen Peng, Zheng SuJun, Wang ShiMei, Zhang JianJun, Xing XinYue, Zhang Ying, Liu Mei, Duan ZhongPing. Selection of siRNA and construction of recombinant lentivirus expressing shRNA targeting rat Smad3 gene[J]. Journal of Clinical Hepatology, 2011, 27(5): 533-537.
[19]	Liu Mei, Zhang LiLi, Chen Ming, Pan XiuCheng, Li Li. The expression of suppressor of cytokine signaling-1 mRNA in the peripheral blood mononuclear cells of patients with chronic hepatitis B infection[J]. Journal of Clinical Hepatology, 2011, 27(5): 500-502.
[20]	Xu QingTian, Ji Ying, Du ShaoCai, Wang HuiMin, Li XinYue, Tao QiMin. Significance of comparing hepatitis C virus (HCV) RNA by polymerase chain reaction between at NS 5b region and 5’-noncoding region[J]. Journal of Clinical Hepatology, 2000, 16(4): 214-215.

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 刘岗生，蔡佳佳. SIRT1与酒精相关性脂肪肝及其与运动关系研究进展. 信阳师范学院学报(自然科学版). 2022(02): 331-337 .
Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (804) PDF downloads(164)

Research advances in non-cirrhotic intrahepatic presinusoidal portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.07.003

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in non-cirrhotic intrahepatic presinusoidal portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.07.003

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content